Infectious Diseases

Blueberry Therapeutics reels in USD 12.7 Million in series B funding for fungal infections. U.K.based, Blueberry Therapeutics successfully bagged a funding of USD 12.7 million in series B funding. The funding will help the company to advance its nanomedicine candidate, BB2603 for two fungal infections namely- Athlete’s foot and fungal nail infections. BB2603 is a nanoformulated form of terbinafine, which is an antifungal treatment, it is currently in the phase 2 and is expected to enter the phase 3 soon after the funding.   Pfizer remunerates Germany’s BioNTech $120M for forming mRNA flu vaccine agreement. Pfizer reimburses a $425 million deal for working ...